Viking Therapeutics Inc (VKTX) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $5. Maxim Group advised their investors in a research report released on May 24, 2016.
Many Wall Street Analysts have commented on Viking Therapeutics Inc. H.C. Wainwright Initiated Viking Therapeutics Inc on Apr 7, 2016 to “Buy”, Price Target of the shares are set at $6.
Viking Therapeutics Inc opened for trading at $1.19 and hit $1.37 on the upside on Friday, eventually ending the session at $1.28, with a gain of 7.56% or 0.09 points. The heightened volatility saw the trading volume jump to 7,60,001 shares. Company has a market cap of $25 M.
In a different news, on Apr 13, 2016, Matthew W Foehr (director) purchased 20,000 shares at $1.24 per share price.
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211 which is an orally available drug candidate under a Phase II clinical trial. Its second clinical program is focused on the development of molecule agonists of the thyroid receptor beta (TRB) for adrenoleukodystrophy (ALD) and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH). The Company is also engaged in developing VK2809 and VK0214 for the treatment and potential prophylaxis of ALD. Its VK0612 is an orally available Phase IIb-ready drug candidate for type 2 diabetes. The Company’s preclinical programs are focused on identifying erythropoietin receptor (EPOR) agonists for the treatment of anemia and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1 (DGAT-1) for the treatment of obesity and dyslipidemia.